MP0250, a First-in-Class DARPin Drug Candidate Targeting VEGF and HGF, in Patients With Advanced Solid Tumors
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Journal of Clinical Oncology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
First-in-Human Phase I Study of MP0250, a First-in-Class DARPin Drug Candidate Targeting VEGF and HGF, in Patients With Advanced Solid Tumors
J. Clin. Oncol 2020 Dec 10;[EPub Ahead of Print], RD Baird, C Linossi, M Middleton, S Lord, A Harris, J Rodón, C Zitt, U Fiedler, KM Dawson, N Leupin, MT Stumpp, A Harstrick, A Azaro, S Fischer, A OmlinFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.